These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 17892420)

  • 1. Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview.
    Hutson TE
    Expert Rev Anticancer Ther; 2007 Sep; 7(9):1193-202. PubMed ID: 17892420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib for the treatment of advanced renal cell carcinoma.
    Kane RC; Farrell AT; Saber H; Tang S; Williams G; Jee JM; Liang C; Booth B; Chidambaram N; Morse D; Sridhara R; Garvey P; Justice R; Pazdur R
    Clin Cancer Res; 2006 Dec; 12(24):7271-8. PubMed ID: 17189398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
    Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Staehler M; Negrier S; Chevreau C; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Anderson S; Hofilena G; Shan M; Pena C; Lathia C; Bukowski RM
    J Clin Oncol; 2009 Jul; 27(20):3312-8. PubMed ID: 19451442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET.
    Hutson TE; Bellmunt J; Porta C; Szczylik C; Staehler M; Nadel A; Anderson S; Bukowski R; Eisen T; Escudier B;
    Eur J Cancer; 2010 Sep; 46(13):2432-40. PubMed ID: 20656473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
    Ratain MJ; Eisen T; Stadler WM; Flaherty KT; Kaye SB; Rosner GL; Gore M; Desai AA; Patnaik A; Xiong HQ; Rowinsky E; Abbruzzese JL; Xia C; Simantov R; Schwartz B; O'Dwyer PJ
    J Clin Oncol; 2006 Jun; 24(16):2505-12. PubMed ID: 16636341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib: a promising new targeted therapy for renal cell carcinoma.
    Wood LS; Manchen B
    Clin J Oncol Nurs; 2007 Oct; 11(5):649-56. PubMed ID: 17962173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib for the management of advanced renal cell carcinoma.
    Escudier B
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):825-36. PubMed ID: 21707277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib: delivering a targeted drug to the right targets.
    Flaherty KT
    Expert Rev Anticancer Ther; 2007 May; 7(5):617-26. PubMed ID: 17492926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.
    Akaza H; Tsukamoto T; Murai M; Nakajima K; Naito S
    Jpn J Clin Oncol; 2007 Oct; 37(10):755-62. PubMed ID: 17951335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib in renal cell carcinoma.
    Flaherty KT
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):747s-752s. PubMed ID: 17255304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.
    Stadler WM; Figlin RA; McDermott DF; Dutcher JP; Knox JJ; Miller WH; Hainsworth JD; Henderson CA; George JR; Hajdenberg J; Kindwall-Keller TL; Ernstoff MS; Drabkin HA; Curti BD; Chu L; Ryan CW; Hotte SJ; Xia C; Cupit L; Bukowski RM;
    Cancer; 2010 Mar; 116(5):1272-80. PubMed ID: 20082451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY; Grossman AB; Bukowski RM
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib in renal cell carcinoma.
    Arranz JÁ; Climent MÁ; González-Larriba JL; León L; Maroto JP
    Crit Rev Oncol Hematol; 2011 Nov; 80(2):314-22. PubMed ID: 21419641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib.
    Hahn O; Stadler W
    Curr Opin Oncol; 2006 Nov; 18(6):615-21. PubMed ID: 16988583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.
    Bukowski RM; Stadler WM; McDermott DF; Dutcher JP; Knox JJ; Miller WH; Hainsworth JD; Henderson CA; Hajdenberg J; Kindwall-Keller TL; Ernstoff MS; Drabkin HA; Curti BD; Chu L; Ryan CW; Hotte SJ; Xia C; Cupit L; Figlin RA
    Oncology; 2010; 78(5-6):340-7. PubMed ID: 20733337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib tosylate in advanced kidney cancer: past, present and future.
    Porta C; Paglino C; Imarisio I; Ferraris E
    Anticancer Drugs; 2009 Jul; 20(6):409-15. PubMed ID: 19436197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma.
    Bilaç C; Müezzinoğlu T; Ermertcan AT; Kayhan TC; Temeltaş G; Oztürkcan S; Temiz P
    Cutan Ocul Toxicol; 2009; 28(2):90-2. PubMed ID: 19514932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients.
    Bellmunt J; Fishman M; Eisen T; Quinn D
    Expert Rev Anticancer Ther; 2010 Jun; 10(6):825-35. PubMed ID: 20553208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.
    Procopio G; Verzoni E; Gevorgyan A; Mancin M; Pusceddu S; Catena L; Platania M; Guadalupi V; Martinetti A; Bajetta E
    Oncology; 2007; 73(3-4):204-9. PubMed ID: 18418013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study.
    Antoun S; Birdsell L; Sawyer MB; Venner P; Escudier B; Baracos VE
    J Clin Oncol; 2010 Feb; 28(6):1054-60. PubMed ID: 20085939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.